Results 71 to 80 of about 8,310 (206)

The Role Of Hmgb1-Related Inflammation Signals In Bronj

open access: yesInternational Dental Journal
Aim or purpose: BRONJ causes prolonged inflammation, resulting in delayed wound healing. High mobility group box-1 (HMGB1) is secreted into the extracellular milieu in response to stimuli, which mediates various inflammatory diseases and affects wound ...
Li Shurong, Yan Jiayi
doaj   +1 more source

Evaluation of Preventive Role of Systemically Applied Erythropoietin after Tooth Extraction in a Bisphosphonate-Induced MRONJ Model

open access: yesMedicina, 2023
Background and Objectives: In this experimental study, the prophylactic effect of systemically administered erythropoietin (EPO) in medication-related osteonecrosis of the jaw (MRONJ) was evaluated.
Gonca Duygu   +4 more
doaj   +1 more source

Physicians’ Preferences for Bone Metastases Drug Therapy in the United States [PDF]

open access: yes, 2015
ObjectiveSeveral characteristics of bone-targeted agents are considered when making treatment decisions. This study evaluated physicians’ therapy preferences for preventing skeletal-related events (SREs) in patients with bone metastases secondary to ...
Arellano, Jorge   +7 more
core   +1 more source

Medication-related osteonecrosis of the jaw: a dentist's nightmare [PDF]

open access: yesBMJ Case Reports, 2016
Medication-related osteonecrosis of the jaw (MRONJ) is a complication in patients who are on anti-bone resorptive drugs. These drugs are prescribed for patients with multiple myeloma, osteoporosis, metastatic carcinoma and Paget's disease. Common anti-bone resorptive drugs such as bisphosphonate and monoclonal antibodies such as denosumab are ...
Arvind, Muthukrishnan   +2 more
openaire   +2 more sources

A maxillary reconstruction after osteonecrosis with surgical biomodels: A case report

open access: yesAdvances in Oral and Maxillofacial Surgery, 2021
Medication-related osteonecrosis of the jaw is a low prevalence condition in cancer patients which is mainly associated with bisphosphonates and other medication therapies, such as antiresorptive and antiangiogenic therapies.
Helena Polmann   +3 more
doaj   +1 more source

Exploring Perimenopausal and Menopausal Women's Oral Health Perceptions and Practices in Australia—A Qualitative Study

open access: yesGerodontology, EarlyView.
ABSTRACT Objective To explore the perceptions and practices of women in peri/menopause towards oral healthcare in Australia. Background Hormonal changes associated with peri/menopause create a period where women may be more prone to developing oral health problems, which can significantly impact their quality of life.
Namitha Thomas   +4 more
wiley   +1 more source

Medication-related osteonecrosis of the jaw in a patient with multiple myeloma

open access: yesJournal of Indian Academy of Oral Medicine and Radiology, 2015
Osteonecrosis of jaws is a common complication of parenteral nitrogen-containing bisphosphonates and recently medication-related osteonecrosis of the jaw (MRONJ) is contributing to the growing number of similar osteonecrosis cases which involve maxilla ...
Nupur Bhardwaj   +3 more
doaj   +1 more source

Medication-related osteonecrosis of the jaw. Introduction of a new modified experimental model [PDF]

open access: yesActa Cirúrgica Brasileira, 2016
PURPOSE : To evaluate a modified experimental model for medication-related osteonecrosis of the jaw (MRONJ) through the upper right central incisor extraction followed by intravenous bisphosphonate administration. METHODS: Forty five rats underwent the
Cláudia Curra   +7 more
doaj   +1 more source

Oral bisphosphonate-related osteonecrosis of the jaws : clinical characteristics of a series of 20 cases in Spain [PDF]

open access: yes, 2012
Objective: The objective of this study was to define the clinical characteristics of osteonecrosis of the jaws (ONJ) induced by oral bisphosphonates in a series of patients from a circumscribed area in northwest Spain.
Diniz Freitas, Márcio   +5 more
core   +1 more source

Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

open access: yesInternal Medicine Journal, EarlyView.
Abstract The role of anti‐resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone‐specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM).
Gayle Radley   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy